The FDA recently approved Acuitive Technology’s CITRELOCK Interference Screw System with CITREGEN Materials Technology, a next-generation thermosetting bioresorbable synthetic polymer. The system is designed to attach tissue during orthopedic surgery.
What makes the CITRELOCK system unique is the use of CITREGEN material technology, explained Mike McCarthy, Managing Partner of Acuitive. DocWire News.
“We designed this device so that it does not damage the tendon during insertion,” said McCarthy. “When you have a typical screw,… those screw threads tear that fabric apart and they compromise the fabric. “
Unlike other products on the market made from a thermoplastic polylactic acid, CITRELOCK is made from a thermosetting material based on citric acid.
“Polylactic acid is a by-product. It must be evacuated from the system, from your body … [With] citritic acid on the other hand, the citrate molecule is absorbed. So this material, the vast majority… is used as an energy source by the body, by the cells ”, he described.
The CITREGEN System also facilitates healing, noted McCarthy: “[Other systems] Expect the body’s healing properties to do all the healing on their own. Our device starts from the first day a process of elution of various molecules.
The device will also be easy to use for surgeons.
“It’s a tapping system rather than a thread system that attacks the tissue you’re trying to move in the anatomy. So [it] protect[s] tissue upon insertion, ”McCarthy explained.
For the future, a lot of exciting news is in preparation for CITREGEN technology in the world of orthopedics. Future possibilities include roles in rotator cuff repair, Achilles tendon repair, diabetic / ulcer wound healing, and the use of larger devices in procedures such as revision surgery.
“This is the most exciting technology that we are affiliated with,” said McCarthy. “We think this has a lot of potential beyond what we’ve done in the past.”